Tracking IndexDynamic Biotech & Genome Intellidex Index (AMEX)
PBE was created on 2005-06-23 by Invesco. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 418.54m in AUM and 32 holdings. PBE tracks a tiered equal-weighted index of companies principally engaged in biotechnology and genetic engineering.
What is the current price of Invesco Biotechnology & Genome ETF (PBE)?
The current price of Invesco Biotechnology & Genome ETF (PBE) is 95.82. Market data may be delayed; please refer to the timestamp displayed on the page.
What is the 52-week high of Invesco Biotechnology & Genome ETF?
The 52-week high of Invesco Biotechnology & Genome ETF is 104.69. Please refer to the page timestamp for the latest data.
What is the 52-week low of Invesco Biotechnology & Genome ETF?
The 52-week low of Invesco Biotechnology & Genome ETF is 74.76. Please refer to the page timestamp for the latest data.
What is the NAV of Invesco Biotechnology & Genome ETF?
The NAV of Invesco Biotechnology & Genome ETF is 98.63 today. NAV represents the fund’s total assets minus its liabilities and helps indicate its underlying per-share value.
How is Invesco Biotechnology & Genome ETF (PBE) performing?
The trading turnover of Invesco Biotechnology & Genome ETF (PBE) is 9.70K. Its price changed by 0.98% over the past month, while its one-year return is 26.76%. View the Invesco Biotechnology & Genome ETF price chart for more details.
Is Invesco Biotechnology & Genome ETF (PBE) a safe investment?
No investment is completely risk-free. The risk level of Invesco Biotechnology & Genome ETF (PBE) depends on its underlying assets, strategy, liquidity, fees, and market conditions. Diversification may reduce potential losses but cannot eliminate them, and past performance does not guarantee future results. Before investing, consider whether the fund aligns with your goals and risk tolerance. This is not investment advice.